



## Small Molecule API Market: APEJ Projected to be the Most Lucrative Regional Market During the Forecast Period: Global Industry Analysis 2012-2016 & Opportunity Assessment 2017-2027

#1392873

\$5000

209 pages

In Stock

### Report Description

The in-depth and thorough report titled “**Small Molecule API Market: Global Industry Analysis 2012-2016 & Opportunity Assessment 2017-2027**” gives the reader a feel and flavour of the market understanding with a wide overview of the market thereby supporting decision making and slating different strategies as and when required.

An exhaustive market research report on the small molecule API market offers weighted analysis of the entire market. Focussing on the major segments and covering all factors that have an influence over the market helps predict the growth rate of the market in the particular regions. Below sketched is the market taxonomy that covers all the segments of the global small molecule API market.

This research study on the small molecule API market delivers value to the reader by making them aware about the past and present scenario of the market. The study also uncovers predictions of the future thereby giving an inkling about the small molecule API market scenario 10 years down the line. It emphasises on the various intelligence acumen such as pricing, product portfolio of various key players present in the market, distribution channel analysis, key developments, trends in present and future, a complete SWOT analysis along with PESTLE analysis and also analysis of the important regions assessed. The study covers revenue generated by API manufacturing including in-house and outsourced manufacturing. The report analyses the demand from in-house production as well as outsourced API production. These insights help plan future decisions and strategic moves that could be easily executed owing to the actionable nature of the understandings present in the report.

#### **An effective research process to ensure maximum proficiency**

At Future Market Insights, the analysts follow a rock-solid research process to allow minimum deviations in the research and reach maximum accuracy. In order to get a 3600 view of the market, a strong secondary research is carried out. Assistance of secondary paid sources is just enough to get going in the correct direction. The secondary research gives a direction to the market definition based on which several primary interviews are

carried out. Key decision makers from several companies within the market are interviewed as well as opinions of market observers are gathered. The data collected from the secondary sources and the corresponding data gathered by primaries is collated and each data point is verified while conversing with the market experts. The best part of this unique methodology is that the data so gathered undergoes evaluation and validation again and again which makes the intelligence extremely accurate giving a realistic shape to the market scenario. A holistic view of the market thus ensures timely and effective strategies to be implemented owing to the data crunching done with reduced or eliminated deviations from the actual face value of the market.

### **Competition analysis**

The research study provides a separate chapter on the competitive landscape, which covers all the major players in the market, along with their details. Facets such as product portfolio analyses, mergers and acquisitions, developments and innovations, key trends followed, market shares and revenues, geographical spread and expansion plans, marketing strategies and pricing intelligence, etc. of the key players are focussed upon. This helps the reader freeze their own milestones and the various strategic moves required to achieve those milestones. The key players include all the tier companies that have a firm hold over the market and can be said to be the face of the market. The intelligence provided on these players enables the reader to understand the “not-to-do” aspects and how to set foot in the right direction.

### **The key value additions that the report offers:**

- The entire report gives credible information with an unbiased interpretation, considering all the possible angles and giving it a holistic view
- The report gives details about each segment present in the market with respect to all important geographies
- The research study enables unparalleled accuracy owing to the use of a robust research methodology
- The research on the past and the present scenario in the global market can give actionable insights on the future; a separate dedicated section on the forecasts helps the reader analyse present moves and predict future actions
- In-depth analysis covers everything giving justice to each segment involved
- The trends, developments, innovations, restraints and challenges faced by every facet is also covered giving a total briefing about the market and uncovering the possible loop holes

---

## **Table Of Content**

---

**Notes:**

**Table Of Content**

**1. Executive Summary**

**2. Market Introduction**

2.1. Market Taxonomy

2.2. Market Definition

**3. Small Molecule Active Pharmaceutical Ingredient Market View Point**

3.1. Macro-Economic Factors

3.2. Opportunity Analysis

3.3. Regulatory Scenario

3.4. Pipeline Assessment

**4. North America Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027**

4.1. Introduction

4.2. Pestle Analysis

4.3. Regional Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Trends

4.4. Historical Market Size (US\$ Mn) Trend Analysis By Country, 2012–2016

4.4.1. U.S.

4.4.2. Canada

4.5. Market Size (US\$ Mn) Forecast By Country, 2017–2027

4.5.1. U.S.

4.5.2. Canada

4.6. Historical Market Size (US\$ Mn) Trend Analysis By Molecule Type, 2012–2016

4.6.1. Standard API

4.6.2. High Potency API

4.7. Market Size (US\$ Mn) Forecast By Molecule Type, 2017–2027

- 4.7.1. Standard API
- 4.7.2. High Potency API
- 4.8. Historical Market Size (US\$ Mn) Trend Analysis By Production, 2012–2016
  - 4.8.1. In-House
  - 4.8.2. Outsourced
- 4.9. Market Size (US\$ Mn) Forecast By Production, 2017–2027
  - 4.9.1. In-House
  - 4.9.2. Outsourced
- 4.10. Historical Market Size (US\$ Mn) Trend Analysis By Application, 2012–2016
  - 4.10.1. Clinical
  - 4.10.2. Commercial
- 4.11. Market Size (US\$ Mn) Analysis By Application, 2017–2027
  - 4.11.1. Clinical
  - 4.11.2. Commercial
- 4.12. Historical Market Size (US\$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
  - 4.12.1. Cardiovascular
  - 4.12.2. Respiratory
  - 4.12.3. Infectious
  - 4.12.4. Metabolic
  - 4.12.5. Oncology
  - 4.12.6. Immunology
  - 4.12.7. Neurology
  - 4.12.8. Urology
  - 4.12.9. Dermatology
  - 4.12.10. Ophthalmology
  - 4.12.11. General Health
  - 4.12.12. Others
- 4.13. Market Size (US\$ Mn) Forecast By Therapeutic Area, 2017–2027
  - 4.13.1. Cardiovascular
  - 4.13.2. Respiratory
  - 4.13.3. Infectious
  - 4.13.4. Metabolic
  - 4.13.5. Oncology
  - 4.13.6. Immunology

- 4.13.7. Neurology
- 4.13.8. Urology
- 4.13.9. Dermatology
- 4.13.10. Ophthalmology
- 4.13.11. General Health
- 4.13.12. Others
- 4.14. Drivers and Restraints: Impact Analysis
- 4.15. Market Attractiveness Analysis
  - 4.15.1. By Country
  - 4.15.2. By Molecule Type
  - 4.15.3. By Production
  - 4.15.4. By Application
  - 4.15.5. By Therapeutic Area
- 4.16. Key Representative Market Participants
- 4.17. Market Presence (Intensity Map)

## **5. Latin America Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027**

- 5.1. Introduction
- 5.2. Regional Market Dynamics
  - 5.2.1. Drivers
  - 5.2.2. Restraints
  - 5.2.3. Trends
- 5.3. Historical Market Size (US\$ Mn) Trend Analysis By Country, 2012–2016
  - 5.3.1. Brazil
  - 5.3.2. Mexico
  - 5.3.3. Rest of Latin America
- 5.4. Market Size (US\$ Mn) Forecast By Country, 2017–2027
  - 5.4.1. Brazil
  - 5.4.2. Mexico
  - 5.4.3. Rest of Latin America
- 5.5. Historical Market Size (US\$ Mn) Trend Analysis By Molecule Type, 2012–2016
  - 5.5.1. Standard API
  - 5.5.2. High Potency API

## 5.6. Market Size (US\$ Mn) Forecast By Molecule Type, 2017–2027

### 5.6.1. Standard API

### 5.6.2. High Potency API

## 5.7. Historical Market Size (US\$ Mn) Trend Analysis By Production, 2012–2016

### 5.7.1. In-House

### 5.7.2. Outsourced

## 5.8. Market Size (US\$ Mn) Forecast By Production, 2017–2027

### 5.8.1. In-House

### 5.8.2. Outsourced

## 5.9. Historical Market Size (US\$ Mn) Trend Analysis By Application, 2012–2016

### 5.9.1. Clinical

### 5.9.2. Commercial

## 5.10. Market Size (US\$ Mn) Analysis By Application, 2017–2027

### 5.10.1. Clinical

### 5.10.2. Commercial

## 5.11. Historical Market Size (US\$ Mn) Trend Analysis By Therapeutic Area, 2012–2016

### 5.11.1. Cardiovascular

### 5.11.2. Respiratory

### 5.11.3. Infectious

### 5.11.4. Metabolic

### 5.11.5. Oncology

### 5.11.6. Immunology

### 5.11.7. Neurology

### 5.11.8. Urology

### 5.11.9. Dermatology

### 5.11.10. Ophthalmology

### 5.11.11. General Health

### 5.11.12. Others

## 5.12. Market Size (US\$ Mn) Forecast By Therapeutic Area, 2017–2027

### 5.12.1. Cardiovascular

### 5.12.2. Respiratory

### 5.12.3. Infectious

### 5.12.4. Metabolic

### 5.12.5. Oncology

- 5.12.6. Immunology
- 5.12.7. Neurology
- 5.12.8. Urology
- 5.12.9. Dermatology
- 5.12.10. Ophthalmology
- 5.12.11. General Health
- 5.12.12. Others
- 5.13. Drivers and Restraints: Impact Analysis
- 5.14. Market Attractiveness Analysis
  - 5.14.1. By Country
  - 5.14.2. By Molecule Type
  - 5.14.3. By Production
  - 5.14.4. By Application
  - 5.14.5. By Therapeutic Area
- 5.15. Key Representative Market Participants
- 5.16. Market Presence (Intensity Map)

## **6. Western Europe Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027**

- 6.1. Introduction
- 6.2. Regional Market Dynamics
  - 6.2.1. Drivers
  - 6.2.2. Restraints
  - 6.2.3. Trends
- 6.3. Historical Market Size (US\$ Mn) Trend Analysis By Country, 2012–2016
  - 6.3.1. Germany
  - 6.3.2. Italy
  - 6.3.3. France
  - 6.3.4. Spain
  - 6.3.5. U.K.
  - 6.3.6. BENELUX
  - 6.3.7. Nordic
  - 6.3.8. Rest of Western Europe
- 6.4. Market Size (US\$ Mn) Forecast By Country, 2017–2027

- 6.4.1. Germany
- 6.4.2. Italy
- 6.4.3. France
- 6.4.4. Spain
- 6.4.5. U.K.
- 6.4.6. BENELUX
- 6.4.7. Nordic
- 6.4.8. Rest of Western Europe
- 6.5. Historical Market Size (US\$ Mn) Trend Analysis By Molecule Type, 2012–2016
  - 6.5.1. Standard API
  - 6.5.2. High Potency API
- 6.6. Market Size (US\$ Mn) Forecast By Molecule Type, 2017–2027
  - 6.6.1. Standard API
  - 6.6.2. High Potency API
- 6.7. Historical Market Size (US\$ Mn) Trend Analysis By Production, 2012–2016
  - 6.7.1. In-House
  - 6.7.2. Outsourced
- 6.8. Market Size (US\$ Mn) Forecast By Production, 2017–2027
  - 6.8.1. In-House
  - 6.8.2. Outsourced
- 6.9. Historical Market Size (US\$ Mn) Trend Analysis By Application, 2012–2016
  - 6.9.1. Clinical
  - 6.9.2. Commercial
- 6.10. Market Size (US\$ Mn) Analysis By Application, 2017–2027
  - 6.10.1. Clinical
  - 6.10.2. Commercial
- 6.11. Historical Market Size (US\$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
  - 6.11.1. Cardiovascular
  - 6.11.2. Respiratory
  - 6.11.3. Infectious
  - 6.11.4. Metabolic
  - 6.11.5. Oncology
  - 6.11.6. Immunology
  - 6.11.7. Neurology



- 6.11.8. Urology
- 6.11.9. Dermatology
- 6.11.10. Ophthalmology
- 6.11.11. General Health
- 6.11.12. Others
- 6.12. Market Size (US\$ Mn) Forecast By Therapeutic Area, 2017–2027
  - 6.12.1. Cardiovascular
  - 6.12.2. Respiratory
  - 6.12.3. Infectious
  - 6.12.4. Metabolic
  - 6.12.5. Oncology
  - 6.12.6. Immunology
  - 6.12.7. Neurology
  - 6.12.8. Urology
  - 6.12.9. Dermatology
  - 6.12.10. Ophthalmology
  - 6.12.11. General Health
  - 6.12.12. Others
- 6.13. Drivers and Restraints: Impact Analysis
- 6.14. Market Attractiveness Analysis
  - 6.14.1. By Country
  - 6.14.2. By Molecule Type
  - 6.14.3. By Production
  - 6.14.4. By Application
  - 6.14.5. By Therapeutic Area
- 6.15. Key Representative Market Participants
- 6.16. Market Presence (Intensity Map)

## **7. Eastern Europe Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027**

- 7.1. Introduction
- 7.2. Historical Market Size (US\$ Mn) Trend Analysis By Country, 2012–2016
  - 7.2.1. Russia
  - 7.2.2. Poland

- 7.2.3. Rest of Eastern Europe
- 7.3. Market Size (US\$ Mn) Forecast By Country, 2017–2027
  - 7.3.1. Russia
  - 7.3.2. Poland
  - 7.3.3. Rest of Eastern Europe
- 7.4. Historical Market Size (US\$ Mn) Trend Analysis By Molecule Type, 2012–2016
  - 7.4.1. Standard API
  - 7.4.2. High Potency API
- 7.5. Market Size (US\$ Mn) Forecast By Molecule Type, 2017–2027
  - 7.5.1. Standard API
  - 7.5.2. High Potency API
- 7.6. Historical Market Size (US\$ Mn) Trend Analysis By Production, 2012–2016
  - 7.6.1. In-House
  - 7.6.2. Outsourced
- 7.7. Market Size (US\$ Mn) Forecast By Production, 2017–2027
  - 7.7.1. In-House
  - 7.7.2. Outsourced
- 7.8. Historical Market Size (US\$ Mn) Trend Analysis By Application, 2012–2016
  - 7.8.1. Clinical
  - 7.8.2. Commercial
- 7.9. Market Size (US\$ Mn) Analysis By Application, 2017–2027
  - 7.9.1. Clinical
  - 7.9.2. Commercial
- 7.10. Historical Market Size (US\$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
  - 7.10.1. Cardiovascular
  - 7.10.2. Respiratory
  - 7.10.3. Infectious
  - 7.10.4. Metabolic
  - 7.10.5. Oncology
  - 7.10.6. Immunology
  - 7.10.7. Neurology
  - 7.10.8. Urology
  - 7.10.9. Dermatology
  - 7.10.10. Ophthalmology

- 7.10.11. General Health
- 7.10.12. Others
- 7.11. Market Size (US\$ Mn) Forecast By Therapeutic Area, 2017–2027
  - 7.11.1. Cardiovascular
  - 7.11.2. Respiratory
  - 7.11.3. Infectious
  - 7.11.4. Metabolic
  - 7.11.5. Oncology
  - 7.11.6. Immunology
  - 7.11.7. Neurology
  - 7.11.8. Urology
  - 7.11.9. Dermatology
  - 7.11.10. Ophthalmology
  - 7.11.11. General Health
  - 7.11.12. Others
- 7.12. Drivers and Restraints: Impact Analysis
- 7.13. Market Attractiveness Analysis
  - 7.13.1. By Country
  - 7.13.2. By Molecule Type
  - 7.13.3. By Production
  - 7.13.4. By Application
  - 7.13.5. By Therapeutic Area
- 7.14. Key Representative Market Participants
- 7.15. Market Presence (Intensity Map)

## **8. Asia Pacific excluding Japan Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027**

- 8.1. Introduction
- 8.2. Regional Market Dynamics
  - 8.2.1. Drivers
  - 8.2.2. Restraints
  - 8.2.3. Trends
- 8.3. Historical Market Size (US\$ Mn) Trend Analysis By Country, 2012–2016
  - 8.3.1. China

- 8.3.2. India
- 8.3.3. ASEAN
- 8.3.4. Australia and New Zealand
- 8.3.5. Rest of APEJ
- 8.4. Market Size (US\$ Mn) Forecast By Country, 2017–2027
  - 8.4.1. China
  - 8.4.2. India
  - 8.4.3. ASEAN
  - 8.4.4. Australia and New Zealand
  - 8.4.5. Rest of APEJ
- 8.5. Historical Market Size (US\$ Mn) Trend Analysis By Molecule Type, 2012–2016
  - 8.5.1. Standard API
  - 8.5.2. High Potency API
- 8.6. Market Size (US\$ Mn) Forecast By Molecule Type, 2017–2027
  - 8.6.1. Standard API
  - 8.6.2. High Potency API
- 8.7. Historical Market Size (US\$ Mn) Trend Analysis By Production, 2012–2016
  - 8.7.1. In-House
  - 8.7.2. Outsourced
- 8.8. Market Size (US\$ Mn) Forecast By Production, 2017–2027
  - 8.8.1. In-House
  - 8.8.2. Outsourced
- 8.9. Historical Market Size (US\$ Mn) Trend Analysis By Application, 2012–2016
  - 8.9.1. Clinical
  - 8.9.2. Commercial
- 8.10. Market Size (US\$ Mn) Analysis By Application, 2017–2027
  - 8.10.1. Clinical
  - 8.10.2. Commercial
- 8.11. Historical Market Size (US\$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
  - 8.11.1. Cardiovascular
  - 8.11.2. Respiratory
  - 8.11.3. Infectious
  - 8.11.4. Metabolic
  - 8.11.5. Oncology

- 8.11.6. Immunology
- 8.11.7. Neurology
- 8.11.8. Urology
- 8.11.9. Dermatology
- 8.11.10. Ophthalmology
- 8.11.11. General Health
- 8.11.12. Others
- 8.12. Market Size (US\$ Mn) Forecast By Therapeutic Area, 2017–2027
  - 8.12.1. Cardiovascular
  - 8.12.2. Respiratory
  - 8.12.3. Infectious
  - 8.12.4. Metabolic
  - 8.12.5. Oncology
  - 8.12.6. Immunology
  - 8.12.7. Neurology
  - 8.12.8. Urology
  - 8.12.9. Dermatology
  - 8.12.10. Ophthalmology
  - 8.12.11. General Health
  - 8.12.12. Others
- 8.13. Drivers and Restraints: Impact Analysis
- 8.14. Market Attractiveness Analysis
  - 8.14.1. By Country
  - 8.14.2. By Molecule Type
  - 8.14.3. By Production
  - 8.14.4. By Application
  - 8.14.5. By Therapeutic Area
- 8.15. Key Representative Market Participants
- 8.16. Market Presence (Intensity Map)

## **9. Japan Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027**

- 9.1. Introduction
- 9.2. Historical Market Size (US\$ Mn) Trend Analysis By Molecule Type, 2012–2016

- 9.2.1. Standard API
- 9.2.2. High Potency API
- 9.3. Market Size (US\$ Mn) Forecast By Molecule Type, 2017–2027
  - 9.3.1. Standard API
  - 9.3.2. High Potency API
- 9.4. Historical Market Size (US\$ Mn) Trend Analysis By Production, 2012–2016
  - 9.4.1. In-House
  - 9.4.2. Outsourced
- 9.5. Market Size (US\$ Mn) Forecast By Production, 2017–2027
  - 9.5.1. In-House
  - 9.5.2. Outsourced
- 9.6. Historical Market Size (US\$ Mn) Trend Analysis By Application, 2012–2016
  - 9.6.1. Clinical
  - 9.6.2. Commercial
- 9.7. Market Size (US\$ Mn) Analysis By Application, 2017–2027
  - 9.7.1. Clinical
  - 9.7.2. Commercial
- 9.8. Historical Market Size (US\$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
  - 9.8.1. Cardiovascular
  - 9.8.2. Respiratory
  - 9.8.3. Infectious
  - 9.8.4. Metabolic
  - 9.8.5. Oncology
  - 9.8.6. Immunology
  - 9.8.7. Neurology
  - 9.8.8. Urology
  - 9.8.9. Dermatology
  - 9.8.10. Ophthalmology
  - 9.8.11. General Health
  - 9.8.12. Others
- 9.9. Market Size (US\$ Mn) Forecast By Therapeutic Area, 2017–2027
  - 9.9.1. Cardiovascular
  - 9.9.2. Respiratory
  - 9.9.3. Infectious

- 9.9.4. Metabolic
- 9.9.5. Oncology
- 9.9.6. Immunology
- 9.9.7. Neurology
- 9.9.8. Urology
- 9.9.9. Dermatology
- 9.9.10. Ophthalmology
- 9.9.11. General Health
- 9.9.12. Others
- 9.10. Drivers and Restraints: Impact Analysis
- 9.11. Market Attractiveness Analysis
  - 9.11.1. By Molecule Type
  - 9.11.2. By Production
  - 9.11.3. By Application
  - 9.11.4. By Therapeutic Area
- 9.12. Key Representative Market Participants
- 9.13. Market Presence (Intensity Map)

## **10. Middle East & Africa Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027**

- 10.1. Introduction
- 10.2. Historical Market Size (US\$ Mn) Trend Analysis By Country, 2012–2016
  - 10.2.1. GCC Countries
  - 10.2.2. Turkey
  - 10.2.3. Northern Africa
  - 10.2.4. South Africa
  - 10.2.5. Rest of MEA
- 10.3. Market Size (US\$ Mn) Forecast By Country, 2017–2027
  - 10.3.1. GCC Countries
  - 10.3.2. Turkey
  - 10.3.3. Northern Africa
  - 10.3.4. South Africa
  - 10.3.5. Rest of MEA
- 10.4. Historical Market Size (US\$ Mn) Trend Analysis By Molecule Type, 2012–2016

- 10.4.1. Standard API
- 10.4.2. High Potency API
- 10.5. Market Size (US\$ Mn) Forecast By Molecule Type, 2017–2027
  - 10.5.1. Standard API
  - 10.5.2. High Potency API
- 10.6. Historical Market Size (US\$ Mn) Trend Analysis By Production, 2012–2016
  - 10.6.1. In-House
  - 10.6.2. Outsourced
- 10.7. Market Size (US\$ Mn) Forecast By Production, 2017–2027
  - 10.7.1. In-House
  - 10.7.2. Outsourced
- 10.8. Historical Market Size (US\$ Mn) Trend Analysis By Application, 2012–2016
  - 10.8.1. Clinical
  - 10.8.2. Commercial
- 10.9. Market Size (US\$ Mn) Analysis By Application, 2017–2027
  - 10.9.1. Clinical
  - 10.9.2. Commercial
- 10.10. Historical Market Size (US\$ Mn) Trend Analysis By Therapeutic Area, 2012–2016
  - 10.10.1. Cardiovascular
  - 10.10.2. Respiratory
  - 10.10.3. Infectious
  - 10.10.4. Metabolic
  - 10.10.5. Oncology
  - 10.10.6. Immunology
  - 10.10.7. Neurology
  - 10.10.8. Urology
  - 10.10.9. Dermatology
  - 10.10.10. Ophthalmology
  - 10.10.11. General Health
  - 10.10.12. Others
- 10.11. Market Size (US\$ Mn) Forecast By Therapeutic Area, 2017–2027
  - 10.11.1. Cardiovascular
  - 10.11.2. Respiratory
  - 10.11.3. Infectious



- 10.11.4. Metabolic
- 10.11.5. Oncology
- 10.11.6. Immunology
- 10.11.7. Neurology
- 10.11.8. Urology
- 10.11.9. Dermatology
- 10.11.10. Ophthalmology
- 10.11.11. General Health
- 10.11.12. Others
- 10.12. Drivers and Restraints: Impact Analysis
- 10.13. Market Attractiveness Analysis
  - 10.13.1. By Country
  - 10.13.2. By Molecule Type
  - 10.13.3. By Production
  - 10.13.4. By Application
  - 10.13.5. By Therapeutic Area
- 10.14. Key Representative Market Participants
- 10.15. Market Presence (Intensity Map)

## **11. Forecast Factors: Relevance and Impact**

## **12. Forecast Assumptions**

## **13. Competition Landscape**

- 13.1. Market Structure
- 13.2. Competition Dashboard
- 13.3. Company Profiles (Details – Overview, Financials, Strategy, SWOT, Recent Developments)
  - 13.3.1. Johnson Matthey
  - 13.3.2. Siegfried Holding AG
  - 13.3.3. Pfizer
  - 13.3.4. Sanofi S.A.
  - 13.3.5. Novartis AG,
  - 13.3.6. Bristol-Myers Squibb,
  - 13.3.7. Boehringer Ingelheim GmbH

- 13.3.8. GlaxoSmithKline PLC, GILEAD Science Inc.,
- 13.3.9. Albany Molecular Research Inc.
- 13.3.10. Bachem Holding AG
- 13.3.11. PCAS
- 13.3.12. Patheon N.V.
- 13.3.13. AstraZeneca
- 13.3.14. Johnson & Johnson
- 13.3.15. Merck & Co, Inc.
- 13.3.16. BASF SE
- 13.3.17. Catalent Inc.
- 13.3.18. Teva Pharmaceuticals
- 13.3.19. F. Hoffmann-La Roche Ltd
- 13.3.20. Cambrex Corporation
- 13.3.21. GILEAD Science Inc.

#### **14. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027, By Region**

- 14.1. Introduction/Key Findings
- 14.2. Historical Market Size (US\$ Mn) Trend Analysis By Region, 2012–2016
  - 14.2.1. North America
  - 14.2.2. Latin America
  - 14.2.3. Western Europe
  - 14.2.4. Eastern Europe
  - 14.2.5. Asia Pacific excluding Japan
  - 14.2.6. Japan
  - 14.2.7. Middle East & Africa
- 14.3. Market Size (US\$ Mn) Forecast By Region, 2017–2027
  - 14.3.1. North America
  - 14.3.2. Latin America
  - 14.3.3. Western Europe
  - 14.3.4. Eastern Europe
  - 14.3.5. Asia Pacific excluding Japan
  - 14.3.6. Japan
  - 14.3.7. Middle East & Africa

14.4. Market Attractiveness Analysis By Region

**15. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type**

15.1. Introduction/Key Findings

15.2. Historical Market Size (US\$ Mn) Trend Analysis By Molecule Type, 2012–2016

15.2.1. Standard API

15.2.2. High Potency API

15.3. Market Size (US\$ Mn) Forecast By Molecule Type, 2017–2027

15.3.1. Standard API

15.3.2. High Potency API

15.4. Market Attractiveness Analysis By Molecule Type

**16. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027, Production**

16.1. Introduction/Key Findings

16.2. Historical Market Size (US\$ Mn) Trend Analysis By Production, 2012–2016

16.2.1. In-House

16.2.2. Outsourced

16.3. Market Size (US\$ Mn) Forecast By Production, 2017–2027

16.3.1. In-House

16.3.2. Outsourced

16.4. Market Attractiveness Analysis By Application

**17. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027, Application**

17.1. Introduction/Key Findings

17.2. Historical Market Size (US\$ Mn) Trend Analysis By Application, 2012–2016

17.2.1. Clinical

17.2.2. Commercial

17.3. Market Size (US\$ Mn) Analysis By Application, 2017–2027

17.3.1. Clinical

17.3.2. Commercial

17.4. Market Attractiveness Analysis By Application

## **18. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027, Therapeutic Area**

18.1. Introduction/Key Findings

18.2. Historical Market Size (US\$ Mn) Trend Analysis By Therapeutic Area, 2012–2016

18.2.1. Cardiovascular

18.2.2. Respiratory

18.2.3. Infectious

18.2.4. Metabolic

18.2.5. Oncology

18.2.6. Immunology

18.2.7. Neurology

18.2.8. Urology

18.2.9. Dermatology

18.2.10. Ophthalmology

18.2.11. General Health

18.2.12. Others

18.3. Market Size (US\$ Mn) Analysis By Therapeutic Area, 2017–2027

18.3.1. Cardiovascular

18.3.2. Respiratory

18.3.3. Infectious

18.3.4. Metabolic

18.3.5. Oncology

18.3.6. Immunology

18.3.7. Neurology

18.3.8. Urology

18.3.9. Dermatology

18.3.10. Ophthalmology

18.3.11. General Health

18.3.12. Others

18.4. Market Attractiveness Analysis By Therapeutic Area

## **19. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027**

19.1. Market Size and Y-o-Y Growth

## 19.2. Absolute \$ Opportunity

Table 01: North America Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 02: North America Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type

Table 03: North America Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production

Table 04: North America Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 05: North America Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Table 06: Western Europe Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 07: Western Europe Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type

Table 08: Western Europe Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production

Table 09: Western Europe Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 10: Western Europe Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Table 11: Eastern Europe Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 12: Eastern Europe Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type

Table 13: Eastern Europe Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production

Table 14: Eastern Europe Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 15: Eastern Europe Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Table 16: Latin America Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 17: Latin America Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type

Table 18: Latin America Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production

Table 19: Latin America Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 20: Latin America Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Table 21: APEJ Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 22: APEJ Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type

Table 23: APEJ Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production

Table 24: APEJ Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 25: APEJ Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Table 26: MEA Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 27: MEA Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type

Table 28: MEA Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production

Table 29: MEA Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 30: MEA Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Table 31: Japan Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type

Table 32: Japan Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production

Table 33: Japan Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 34: Japan Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Table 35: Global Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type

Table 36: Global Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production

Table 37: Global Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 38: Global Small Molecule API Market Size (US\$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Figure 01: North America Small Molecule API Historical Market Size Analysis, 2012–2016

Figure 02: North America Small Molecule API Market Forecast, 2017–2017

Figure 03: North America Standard API Historical Market Size Analysis, 2012–2016

Figure 04: North America Standard API Market Forecast, 2017–2017

Figure 05: North America High Potency API Historical Market Size Analysis, 2012–2016

Figure 06: North America High Potency API Market Forecast, 2017–2017

Figure 07: North America Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016

Figure 08: North America Small Molecule API Market Forecast, By In-House, 2017–2017

Figure 09: North America Small Molecule API Historical Market Size Analysis, By Outsourced, 2012–2016

Figure 10: North America Small Molecule API Market Forecast, By Outsourced, 2017–2017

Figure 11: North America Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016

Figure 12: North America Small Molecule API Market Forecast by Clinical, 2017–2017

Figure 13: North America Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016

Figure 14: North America Small Molecule API Market Forecast by Commercial, 2017–2017

Figure 15: North America Small Molecule API Market Attractiveness Analysis, By Country

Figure 16: North America Small Molecule API Market Attractiveness Analysis, By Molecule Type

Figure 17: North America Small Molecule API Market Attractiveness Analysis, By Production

Figure 18: North America Small Molecule API Market Attractiveness Analysis, Application

Figure 19: North America Small Molecule API Market Attractiveness Analysis, By Therapeutic Area

Figure 20: Western Europe Small Molecule API Historical Market Size Analysis, 2012–2016

Figure 21: Western Europe Small Molecule API Market Forecast, 2017–2017

Figure 22: Western Europe Standard API Historical Market Size Analysis, 2012–2016

Figure 23: Western Europe Standard API Market Forecast, 2017–2017

- Figure 24: Western Europe High Potency API Historical Market Size Analysis, 2012–2016
- Figure 25: Western Europe High Potency API Market Forecast, 2017–2017
- Figure 26: Western Europe Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016
- Figure 27: Western Europe Small Molecule API Market Forecast, By In-House, 2017–2017
- Figure 28: Western Europe Small Molecule API Historical Market Size Analysis, By Outsourced, 2012–2016
- Figure 29: Western Europe Small Molecule API Market Forecast, By Outsourced, 2017–2017
- Figure 30: Western Europe Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016
- Figure 31: Western Europe Small Molecule API Market Forecast, By Clinical, 2017–2017
- Figure 32: Western Europe Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016
- Figure 33: Western Europe Small Molecule API Market Forecast, By Commercial, 2017–2017
- Figure 34: Western Europe Small Molecule API Market Attractiveness Analysis, By Country
- Figure 35: Western Europe Small Molecule API Market Attractiveness Analysis, By Molecule Type
- Figure 36: Western Europe Small Molecule API Market Attractiveness Analysis, By Production
- Figure 37: Western Europe Small Molecule API Market Attractiveness Analysis, Application
- Figure 38: Western Europe Small Molecule API Market Attractiveness Analysis, By Therapeutic Area
- Figure 39: Eastern Europe Small Molecule API Historical Market Size Analysis, 2012–2016
- Figure 40: Eastern Europe Small Molecule API Market Forecast, 2017–2017
- Figure 41: Eastern Europe Standard API Historical Market Size Analysis, 2012–2016
- Figure 42: Eastern Europe Standard API Market Forecast, 2017–2017
- Figure 43: Eastern Europe High Potency API Historical Market Size Analysis, 2012–2016
- Figure 44: Eastern Europe High Potency API Market Forecast, 2017–2017
- Figure 45: Eastern Europe Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016
- Figure 46: Eastern Europe Small Molecule API Market Forecast, By In-House, 2017–2017
- Figure 47: Eastern Europe Small Molecule API Historical Market Size Analysis, By Outsourced, 2012–2016
- Figure 48: Eastern Europe Small Molecule API Market Forecast, By Outsourced, 2017–2017
- Figure 49: Eastern Europe Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016
- Figure 50: Eastern Europe Small Molecule API Market Forecast, By Clinical, 2017–2017
- Figure 51: Eastern Europe Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016
- Figure 52: Eastern Europe Small Molecule API Market Forecast, By Commercial, 2017–2017
- Figure 53: Eastern Europe Small Molecule API Market Attractiveness Analysis, By Country
- Figure 54: Eastern Europe Small Molecule API Market Attractiveness Analysis, By Molecule Type
- Figure 55: Eastern Europe Small Molecule API Market Attractiveness Analysis, By Production
- Figure 56: Eastern Europe Small Molecule API Market Attractiveness Analysis, Application
- Figure 57: Eastern Europe Small Molecule API Market Attractiveness Analysis, By Therapeutic Area



- Figure 58: Latin America Small Molecule API Historical Market Size Analysis, 2012–2016
- Figure 59: Latin America Small Molecule API Market Forecast, 2017–2017
- Figure 60: Latin America Standard API Historical Market Size Analysis, 2012–2016
- Figure 61: Latin America Standard API Market Forecast, 2017–2017
- Figure 62: Latin America High Potency API Historical Market Size Analysis, 2012–2016
- Figure 63: Latin America High Potency API Market Forecast, 2017–2017
- Figure 64: Latin America Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016
- Figure 65: Latin America Small Molecule API Market Forecast, By In-House, 2017–2017
- Figure 66: Latin America Small Molecule API Historical Market Size Analysis, By Outsourced, 2012–2016
- Figure 67: Latin America Small Molecule API Market Forecast, By Outsourced, 2017–2017
- Figure 68: Latin America Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016
- Figure 69: Latin America Small Molecule API Market Forecast, By Clinical, 2017–2017
- Figure 70: Latin America Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016
- Figure 71: Latin America Small Molecule API Market Forecast, By Commercial, 2017–2017
- Figure 72: Latin America Small Molecule API Market Attractiveness Analysis, By Country
- Figure 73: Latin America Small Molecule API Market Attractiveness Analysis, By Molecule Type
- Figure 74: Latin America Small Molecule API Market Attractiveness Analysis, By Production
- Figure 75: Latin America Small Molecule API Market Attractiveness Analysis, Application
- Figure 76: Latin America Small Molecule API Market Attractiveness Analysis, By Therapeutic Area
- Figure 77: APEJ Small Molecule API Historical Market Size Analysis, 2012–2016
- Figure 78: APEJ Small Molecule API Market Forecast, 2017–2017
- Figure 79: APEJ Standard API Historical Market Size Analysis, 2012–2016
- Figure 80: APEJ Standard API Market Forecast, 2017–2017
- Figure 81: APEJ High Potency API Historical Market Size Analysis, 2012–2016
- Figure 82: APEJ High Potency API Market Forecast, 2017–2017
- Figure 83: APEJ Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016
- Figure 84: APEJ Small Molecule API Market Forecast, By In-House, 2017–2017
- Figure 85: APEJ Small Molecule API Historical Market Size Analysis, By Outsourced, 2012–2016
- Figure 86: APEJ Small Molecule API Market Forecast By Outsourced, 2017–2017
- Figure 87: APEJ Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016
- Figure 88: APEJ Small Molecule API Market Forecast, By Clinical, 2017–2017
- Figure 89: APEJ Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016
- Figure 90: APEJ Small Molecule API Market Forecast, By Commercial, 2017–2017
- Figure 91: APEJ Small Molecule API Market Attractiveness Analysis, By Country

- Figure 92: APEJ Small Molecule API Market Attractiveness Analysis, By Molecule Type
- Figure 93: APEJ Small Molecule API Market Attractiveness Analysis, By Production
- Figure 94: APEJ Small Molecule API Market Attractiveness Analysis, Application
- Figure 95: APEJ Small Molecule API Market Attractiveness Analysis, By Therapeutic Area
- Figure 96: MEA Small Molecule API Historical Market Size Analysis, 2012–2016
- Figure 97: MEA Small Molecule API Market Forecast, 2017–2017
- Figure 98: MEA Standard API Historical Market Size Analysis, 2012–2016
- Figure 99: MEA Standard API Market Forecast, 2017–2017
- Figure 100: MEA High Potency API Historical Market Size Analysis, 2012–2016
- Figure 101: MEA High Potency API Market Forecast, 2017–2017
- Figure 102: MEA Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016
- Figure 103: MEA Small Molecule API Market Forecast, By In-House, 2017–2017
- Figure 104: MEA Small Molecule API Historical Market Size Analysis, By Outsourced, 2012–2016
- Figure 105: MEA Small Molecule API Market Forecast, By Outsourced, 2017–2017
- Figure 106: MEA Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016
- Figure 107: MEA Small Molecule API Market Forecast, By Clinical, 2017–2017
- Figure 108: MEA Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016
- Figure 109: MEA Small Molecule API Market Forecast, By Commercial, 2017–2017
- Figure 110: MEA Small Molecule API Market Attractiveness Analysis, By Country
- Figure 111: MEA Small Molecule API Market Attractiveness Analysis, By Molecule Type
- Figure 112: MEA Small Molecule API Market Attractiveness Analysis, By Production
- Figure 113: MEA Small Molecule API Market Attractiveness Analysis, Application
- Figure 114: MEA Small Molecule API Market Attractiveness Analysis, By Therapeutic Area
- Figure 115: Japan Small Molecule API Historical Market Size Analysis, 2012–2016
- Figure 116: Japan Small Molecule API Market Forecast, 2017–2017
- Figure 117: Japan Standard API Historical Market Size Analysis, 2012–2016
- Figure 118: Japan Standard API Market Forecast, 2017–2017
- Figure 119: Japan High Potency API Historical Market Size Analysis, 2012–2016
- Figure 120: Japan High Potency API Market Forecast, 2017–2017
- Figure 121: Japan Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016
- Figure 122: Japan Small Molecule API Market Forecast, By In-House, 2017–2017
- Figure 123: Japan Small Molecule API Historical Market Size Analysis, By Outsourced, 2012–2016
- Figure 124: Japan Small Molecule API Market Forecast, By Outsourced, 2017–2017
- Figure 125: Japan Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016

- Figure 126: Japan Small Molecule API Market Forecast, By Clinical, 2017–2017
- Figure 127: Japan Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016
- Figure 128: Japan Small Molecule API Market Forecast, By Commercial, 2017–2017
- Figure 129: Japan Small Molecule API Market Attractiveness Analysis, By Molecule Type
- Figure 130: Japan Small Molecule API Market Attractiveness Analysis, By Production
- Figure 131: Japan Small Molecule API Market Attractiveness Analysis, Application
- Figure 132: Japan Small Molecule API Market Attractiveness Analysis, By Therapeutic Area
- Figure 133: Global Small Molecule API Market Size Analysis, 2012–2016
- Figure 134: Global Small Molecule API Market Forecast, 2017–2017
- Figure 135: Global Standard API Historical Market Size Analysis, 2012–2016
- Figure 136: Global Standard API Market Forecast, 2017–2017
- Figure 137: Global High Potency API Historical Market Size Analysis, 2012–2016
- Figure 138: Global High Potency API Market Forecast, 2017–2017
- Figure 139: Global Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016
- Figure 140: Global Small Molecule API Market Forecast, By In-House, 2017–2017
- Figure 141: Global Small Molecule API Historical Market Size Analysis By, Outsourced, 2012–2016
- Figure 142: Global Small Molecule API Market Forecast, By Outsourced, 2017–2017
- Figure 143: Global Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016
- Figure 144: Global Small Molecule API Market Forecast, By Clinical, 2017–2017
- Figure 145: Global Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016
- Figure 146: Global Small Molecule API Market Forecast, By Commercial, 2017–2017
- Figure 147: Global Small Molecule API Market Attractiveness Analysis, By Country
- Figure 148: Global Small Molecule API Market Attractiveness Analysis, By Molecule Type
- Figure 149: Global Small Molecule API Market Attractiveness Analysis, By Production
- Figure 150: Global Small Molecule API Market Attractiveness Analysis, Application
- Figure 151: Global Small Molecule API Market Attractiveness Analysis, By Therapeutic Area

## Buy This Report

Single License : **\$ 5000**



Request sample of this report



Check discount this report



**Go For Report**

<https://www.marketresearchreports.biz/reports/1392873/small-molecule-api-apej-projected-market-research-reports>

---

**Office: United States**

State Tower, 90 State Street, Suite 700, Albany,  
NY 12207, United States

Toll Free: 866-997-4948 (USA-Canada)

Tel: +1-518-621-2074

E: [sales@marketresearchreports.biz](mailto:sales@marketresearchreports.biz)